Maternal vaccination with a novel chimeric glycoprotein formulated with a polymer-based adjuvant provides protection from human parainfluenza virus type 3 in newborn lambs.


Journal

Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699

Informations de publication

Date de publication:
02 2019
Historique:
received: 03 08 2018
revised: 11 11 2018
accepted: 11 12 2018
pubmed: 15 12 2018
medline: 11 2 2020
entrez: 15 12 2018
Statut: ppublish

Résumé

Human parainfluenza virus 3 (PIV3) and respiratory syncytial virus (RSV) are major causative agents of serious respiratory tract illness in newborns and infants. Maternal vaccination could be a promising approach to provide immediate protection against severe PIV3 and RSV infection in young infants. Previously, we demonstrated that maternal immunization with a subunit vaccine consisting of the RSV fusion (F) protein formulated with TriAdj, an adjuvant consisting of poly(I:C), immune defense regulatory peptide and polyphosphazene, protects newborn lambs from RSV. In the present study we evaluated the protective efficacy of a novel bivalent RSV-PIV3 vaccine candidate, F

Identifiants

pubmed: 30550799
pii: S0166-3542(18)30464-9
doi: 10.1016/j.antiviral.2018.12.010
pii:
doi:

Substances chimiques

Adjuvants, Immunologic 0
Antibodies, Neutralizing 0
Antibodies, Viral 0
Glycoproteins 0
Parainfluenza Vaccines 0
Vaccines, Subunit 0
Viral Fusion Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

54-60

Subventions

Organisme : CIHR
ID : MOP 119473
Pays : Canada

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

R Garg (R)

VIDO-InterVac, University of Saskatchewan, Saskatoon, SK, S7N 5E3, Canada.

L Latimer (L)

VIDO-InterVac, University of Saskatchewan, Saskatoon, SK, S7N 5E3, Canada.

S Gomis (S)

Veterinary Pathology, University of Saskatchewan, Saskatoon, SK, S7N 5B4, Canada.

V Gerdts (V)

VIDO-InterVac, University of Saskatchewan, Saskatoon, SK, S7N 5E3, Canada; Veterinary Microbiology, University of Saskatchewan, Saskatoon, SK, S7N 5B4E, Canada.

A Potter (A)

VIDO-InterVac, University of Saskatchewan, Saskatoon, SK, S7N 5E3, Canada; Veterinary Microbiology, University of Saskatchewan, Saskatoon, SK, S7N 5B4E, Canada.

S van Drunen Littel-van den Hurk (S)

VIDO-InterVac, University of Saskatchewan, Saskatoon, SK, S7N 5E3, Canada; Microbiology & Immunology, University of Saskatchewan, Saskatoon, SK, S7N 5E5, Canada. Electronic address: sylvia.vandenhurk@usask.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH